Relay Therapeutics (RLAY)
Market Price (5/12/2026): $12.85 | Market Cap: $2.3 BilSector: Health Care | Industry: Biotechnology
Relay Therapeutics (RLAY)
Market Price (5/12/2026): $12.85Market Cap: $2.3 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -26% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 39% Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, Targeted Therapies, and Computational Drug Discovery. | Weak multi-year price returns3Y Excs Rtn is -68% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -296 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2777% Expensive valuation multiplesP/SPrice/Sales ratio is 216x Stock price has recently run up significantly6M Rtn6 month market price return is 108%, 12M Rtn12 month market price return is 328% Weak revenue growthRev Chg QQuarterly Revenue Change % is -61% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 502% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1998%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1999% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 127% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -16% Key risksRLAY key risks include [1] a heavy reliance on the pivotal clinical trial outcome and regulatory approval of its lead candidate RLY-2608, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -26% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 39% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, Targeted Therapies, and Computational Drug Discovery. |
| Weak multi-year price returns3Y Excs Rtn is -68% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -296 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2777% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 216x |
| Stock price has recently run up significantly6M Rtn6 month market price return is 108%, 12M Rtn12 month market price return is 328% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -61% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 502% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1998%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1999% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 127% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -16% |
| Key risksRLAY key risks include [1] a heavy reliance on the pivotal clinical trial outcome and regulatory approval of its lead candidate RLY-2608, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Regulatory and Clinical Advancements for Zovegalisib.
Relay Therapeutics received a significant boost on February 3, 2026, when the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to zovegalisib (RLY-2608) in combination with fulvestrant for PIK3CA-mutant, HR+/HER2- advanced breast cancer. This designation aims to accelerate the development and review of the therapy. Further positive clinical data was announced, including interim Phase 1/2 ReDiscover trial results presented on March 16, 2026, for zovegalisib plus fulvestrant at the Phase 3 dose, demonstrating an 11.1-month median Progression-Free Survival (PFS) in CDK4/6-experienced patients. Additionally, clinical data for the zovegalisib plus atirmociclib triplet combination, supportive of further development in frontline metastatic breast cancer, was announced on April 27, 2026, showing a 44% objective response rate in heavily pre-treated patients.
2. Strengthened Financial Position and Extended Cash Runway.
The company significantly bolstered its financial standing, reporting approximately $642.1 million in cash, cash equivalents, and investments as of March 31, 2026. This represents an increase from $554.5 million at the end of December 31, 2025, primarily driven by $137.1 million in net proceeds from "at-the-market" offerings during the first quarter of 2026. Management projects that these cash reserves will be sufficient to fund operating expenses and capital expenditure requirements into 2029.
Show more
Stock Movement Drivers
Fundamental Drivers
The 67.8% change in RLAY stock from 1/31/2026 to 5/11/2026 was primarily driven by a 37.0% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5112026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.66 | 12.85 | 67.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 8 | 11 | 27.8% |
| P/S Multiple | 158.0 | 216.5 | 37.0% |
| Shares Outstanding (Mil) | 172 | 180 | -4.1% |
| Cumulative Contribution | 67.8% |
Market Drivers
1/31/2026 to 5/11/2026| Return | Correlation | |
|---|---|---|
| RLAY | 67.8% | |
| Market (SPY) | 3.6% | 31.1% |
| Sector (XLV) | -7.2% | 34.1% |
Fundamental Drivers
The 80.0% change in RLAY stock from 10/31/2025 to 5/11/2026 was primarily driven by a 47.9% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5112026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.14 | 12.85 | 80.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 8 | 11 | 27.8% |
| P/S Multiple | 146.3 | 216.5 | 47.9% |
| Shares Outstanding (Mil) | 171 | 180 | -4.8% |
| Cumulative Contribution | 80.0% |
Market Drivers
10/31/2025 to 5/11/2026| Return | Correlation | |
|---|---|---|
| RLAY | 80.0% | |
| Market (SPY) | 5.5% | 26.3% |
| Sector (XLV) | -0.0% | 28.5% |
Fundamental Drivers
The 285.9% change in RLAY stock from 4/30/2025 to 5/11/2026 was primarily driven by a 288.3% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5112026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.33 | 12.85 | 285.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 10 | 11 | 6.7% |
| P/S Multiple | 55.7 | 216.5 | 288.3% |
| Shares Outstanding (Mil) | 168 | 180 | -6.9% |
| Cumulative Contribution | 285.9% |
Market Drivers
4/30/2025 to 5/11/2026| Return | Correlation | |
|---|---|---|
| RLAY | 285.9% | |
| Market (SPY) | 30.4% | 30.6% |
| Sector (XLV) | 3.6% | 32.6% |
Fundamental Drivers
The 13.0% change in RLAY stock from 4/30/2023 to 5/11/2026 was primarily driven by a 673.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302023 | 5112026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.37 | 12.85 | 13.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 11 | 673.1% |
| P/S Multiple | 996.7 | 216.5 | -78.3% |
| Shares Outstanding (Mil) | 121 | 180 | -32.7% |
| Cumulative Contribution | 13.0% |
Market Drivers
4/30/2023 to 5/11/2026| Return | Correlation | |
|---|---|---|
| RLAY | 13.0% | |
| Market (SPY) | 78.7% | 36.5% |
| Sector (XLV) | 12.6% | 33.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| RLAY Return | -26% | -51% | -26% | -63% | 105% | 51% | -69% |
| Peers Return | 6% | -13% | 60% | 4% | 85% | 47% | 319% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| RLAY Win Rate | 42% | 42% | 50% | 33% | 75% | 40% | |
| Peers Win Rate | 52% | 45% | 58% | 47% | 58% | 56% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| RLAY Max Drawdown | -37% | -57% | -60% | -63% | -51% | -13% | |
| Peers Max Drawdown | -23% | -63% | -38% | -27% | -42% | -8% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: RVMD, IDYA, NUVL, TNGX, KYMR.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/11/2026 (YTD)
How Low Can It Go
| Event | RLAY | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -51.9% | -18.8% |
| % Gain to Breakeven | 108.0% | 23.1% |
| Time to Breakeven | 167 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -49.8% | -9.5% |
| % Gain to Breakeven | 99.2% | 10.5% |
| Time to Breakeven | 75 days | 24 days |
In The Past
Relay Therapeutics's stock fell -51.9% during the 2025 US Tariff Shock. Such a loss loss requires a 108.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | RLAY | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -51.9% | -18.8% |
| % Gain to Breakeven | 108.0% | 23.1% |
| Time to Breakeven | 167 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -49.8% | -9.5% |
| % Gain to Breakeven | 99.2% | 10.5% |
| Time to Breakeven | 75 days | 24 days |
In The Past
Relay Therapeutics's stock fell -51.9% during the 2025 US Tariff Shock. Such a loss loss requires a 108.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Relay Therapeutics (RLAY)
AI Analysis | Feedback
Here are 1-3 brief analogies for Relay Therapeutics:
- Relay Therapeutics is like a Nvidia for drug discovery.
- It's a Google DeepMind for discovering new medicines.
- Think of it as a Moderna for computationally-designed small molecule precision medicines.
AI Analysis | Feedback
```html- RLY-4008: An oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), currently in clinical trials for advanced or metastatic FGFR2-altered solid tumors.
- RLY-2608: A lead mutant-PI3Ka inhibitor program designed to target phosphoinositide 3 kinase alpha.
- RLY-1971: An oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2), undergoing Phase 1 trials for advanced solid tumors.
AI Analysis | Feedback
Relay Therapeutics (RLAY) is a clinical-stage precision medicines company. As such, it is currently focused on the research and development of drug candidates, which are still in various stages of clinical trials. The company does not yet have commercialized products available for sale to individuals or other companies.
Therefore, Relay Therapeutics does not currently have major customers in the traditional sense of selling commercial products. Its revenue streams typically come from collaborations, licensing agreements, and capital financing activities.
AI Analysis | Feedback
- D. E. Shaw Research, LLC
- Genentech, Inc. (Symbol: RHHBY or ROG.SW)
AI Analysis | Feedback
Sanjiv K. Patel, M.A., M.D., MBA President & Chief Executive Officer
Sanjiv Patel brings over 20 years of experience in the life sciences industry to Relay Therapeutics, where he has served as President and Chief Executive Officer since March 2017. Prior to joining Relay Therapeutics, he spent more than a decade at Allergan. At Allergan, he held various leadership positions, including Chief Strategy Officer, where he was involved in significant industry transactions. He also led global strategic marketing for all franchises and was responsible for general management of Allergan's emerging markets. Before Allergan, Mr. Patel was a management consultant at Boston Consulting Group and began his career as a surgeon in the U.K.'s National Health Service.
Tom Catinazzo Chief Financial Officer
Tom Catinazzo has served as Chief Financial Officer of Relay Therapeutics since January 2022. He initially joined Relay Therapeutics in April 2018 as Vice President of Finance and was later promoted to Senior Vice President of Finance in August 2020. Before his tenure at Relay, Mr. Catinazzo held progressively responsible roles in financial planning and analysis at Foundation Medicine from 2013 to 2018. His prior experience also includes positions at Aileron Therapeutics and Genzyme Corporation.
Don Bergstrom, M.D., Ph.D. President, R&D
Don Bergstrom oversees Relay Therapeutics' research and development initiatives, shaping the company's portfolio of medicines by applying insights into protein motion. He became President, R&D in January 2022, having previously served as Executive Vice President, Head of Research and Development since April 2018. Prior to joining Relay, Dr. Bergstrom was the Chief Medical Officer at Mersana Therapeutics, where he was responsible for the non-clinical and early clinical development of two products from their antibody-drug conjugate platform. His career also includes leadership roles in translational medicine and early clinical development at Sanofi Genzyme Oncology and Merck Research Laboratories. Dr. Bergstrom currently serves on the Board of Directors of Cellectis.
Peter Rahmer Chief Corporate Development Officer
Peter Rahmer holds the position of Chief Corporate Development Officer at Relay Therapeutics.
Jim Watters, Ph.D. Chief Scientific Officer
Jim Watters serves as the Chief Scientific Officer at Relay Therapeutics.
AI Analysis | Feedback
The key risks to Relay Therapeutics' business operations are primarily centered around the inherent challenges of being a clinical-stage biopharmaceutical company.
- Clinical Trial Failure and Regulatory Approval: As a clinical-stage company with no approved products, Relay Therapeutics' success hinges on its ability to advance its lead product candidates, RLY-4008, RLY-2608, and RLY-1971, through various phases of clinical trials and ultimately secure regulatory approval. Clinical trials, especially in oncology, carry significant risks related to efficacy and safety concerns, with potential setbacks or negative results having severe consequences. Regulatory hurdles are also substantial, as agencies like the FDA have stringent and evolving requirements for drug approval, and increased scrutiny on accelerated approval pathways can raise clinical trial risk. Even if successful in trials, there is no guarantee of gaining market access due to pricing environments or reimbursement policies.
- Intense Competition: The biotechnology and pharmaceutical industries are highly competitive, characterized by rapid innovation. Relay Therapeutics faces significant competition from larger companies possessing greater resources, which could lead to others developing and commercializing products more successfully. For instance, the acquisition of Scorpion Therapeutics by Eli Lilly has intensified competition in the PI3Ka inhibitor space, directly impacting Relay's RLY-2608 program and potentially eroding its market share or first-mover advantage.
- Dependence on Additional Funding: With a limited operating history and no revenue generated from product sales, Relay Therapeutics has incurred significant operating losses and an accumulated deficit of $2.0 billion as of December 31, 2025. The company's future success is heavily reliant on its ability to secure substantial additional funding to support its ongoing research and development activities and clinical trials. Without sufficient capital, Relay Therapeutics may be forced to delay, reduce, or eliminate critical product development programs or commercialization efforts, adversely affecting its business prospects and competitive position. While the company has extended its cash runway into 2029, inflationary pressures are increasing clinical trial operational costs.
AI Analysis | Feedback
nullAI Analysis | Feedback
Relay Therapeutics (RLAY) has three main product candidates with the following addressable market sizes:- RLY-4008 (FGFR2 inhibitor for advanced or metastatic FGFR2-altered solid tumors): The global Fibroblast Growth Factor Receptor (FGFR) inhibitor market was valued at approximately $185.8 million in 2025 and is projected to grow to about $614.4 million by 2035, with a yearly growth rate of approximately 12.7%. This market growth is driven by increasing cases of FGFR-driven cancers, such as bladder, bile duct, and lung cancer, and advancements in personalized medicine. The 7MM (United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) market for FGFR inhibitors is also expected to surge significantly by 2034.
- RLY-2608 (mutant-PI3Ka inhibitor): The global PI3K inhibitor drug class market was valued at $1.45 billion in 2024, increased to $1.53 billion in 2025, and is expected to reach $2.3 billion by 2033, growing at a compound annual growth rate (CAGR) of 5.5% from 2026 to 2033. More specifically, the market for isoform-selective PI3K inhibitors, which includes PI3K alpha inhibitors, is projected to reach $5.5 billion by 2032 globally. North America held the largest revenue share in the global PI3K inhibitor drug class market in 2025.
- RLY-1971 (oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 for advanced solid tumors): null
AI Analysis | Feedback
Relay Therapeutics (RLAY) is poised for future revenue growth over the next 2-3 years, driven primarily by its advanced pipeline assets and strategic collaborations. The company's revenue for Q4 2025 was $7.0 million, and for the full year 2025, it reached $15.4 million, predominantly from licensing agreements.
Here are the expected drivers of future revenue growth:
- Milestone Payments and Royalties from RLY-4008 Licensing Deal: In December 2024, Relay Therapeutics licensed the exclusive global development and commercialization rights for its FGFR2 inhibitor, RLY-4008 (lirafugratinib), to Elevar Therapeutics. This agreement entitles Relay to receive $75 million in upfront and regulatory milestones, up to $425 million in potential commercial milestones, and royalties on future product sales, providing a significant source of non-dilutive funding.
- Commercialization and Market Penetration of RLY-2608 (Zovegalisib): RLY-2608, an allosteric PI3Kα inhibitor, is Relay's lead asset and is currently in Phase 3 trials (ReDiscover-2) for HR+/HER2- metastatic breast cancer, with initiation of the pivotal study anticipated in mid-2025. The drug has demonstrated promising safety and efficacy in earlier trials, achieving a median progression-free survival of 11.0 to 11.4 months in second-line patients, and has received FDA Breakthrough Therapy designation. Analysts project a multi-billion dollar market potential for RLY-2608 upon potential approval and launch within the forecast period.
- Expansion of RLY-2608 into Additional Indications and Earlier Lines of Therapy: Beyond its initial focus on second-line HR+/HER2- metastatic breast cancer, Relay Therapeutics is exploring the potential of RLY-2608 in earlier lines of breast cancer therapy through triplet combinations and for PIK3CA-driven vascular anomalies. Successful development and approval in these broader indications would significantly expand the addressable market and contribute to long-term revenue growth.
- Potential for New Collaboration and Licensing Agreements: Relay Therapeutics continues to leverage its proprietary Dynamo® platform to advance a pipeline of precision medicines in oncology and genetic diseases. The company aims to advance its Fabry and NRAS programs to Investigational New Drug (IND) readiness. Future partnerships or out-licensing deals for these or other early-stage assets, similar to the Elevar Therapeutics agreement for RLY-4008, could generate additional upfront payments, milestones, and royalties, contributing to revenue growth.
AI Analysis | Feedback
Share Issuance
- Relay Therapeutics completed a public offering in September 2024, issuing 28,571,429 shares of common stock at $7.00 per share, which generated gross proceeds of approximately $200 million.
- In January 2024, the company completed a private placement financing, selling 2.5 million shares of common stock at $12.00 per share, resulting in gross proceeds of $30.0 million.
- A new US$96.2 million shelf registration for potential common stock issuance was reported in March 2026.
Inbound Investments
- As of December 31, 2025, Relay Therapeutics reported cash, cash equivalents, and investments totaling approximately $554.5 million, a decrease from $781.3 million as of December 31, 2024.
- The company's revenue for 2025 was $15.4 million, an increase from $10.0 million in 2024, primarily driven by an exclusive license agreement with Elevar Therapeutics, Inc.
Outbound Investments
- Relay Therapeutics acquired ZebiAI Therapeutics, Inc. in April 2021.
- The upfront consideration for the ZebiAI acquisition was $85 million, comprising $20 million in cash and $65 million in Relay Therapeutics common stock.
- ZebiAI stockholders are eligible to receive up to an additional $85 million in milestone payments, payable in common stock, and up to $100 million in cash from future partnering agreements related to ZebiAI's platform.
Capital Expenditures
- Capital expenditures for the most recent fiscal year (likely 2025) were -$410,000.
- Capital expenditures for the last 12 months (as of March 2026) were approximately -$410,000.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to RLAY.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 56.11 |
| Mkt Cap | 5.7 |
| Rev LTM | 31 |
| Op Inc LTM | -326 |
| FCF LTM | -229 |
| FCF 3Y Avg | -208 |
| CFO LTM | -228 |
| CFO 3Y Avg | -201 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 43.7% |
| Rev Chg 3Y Avg | 490.8% |
| Rev Chg Q | -60.9% |
| QoQ Delta Rev Chg LTM | -1.6% |
| Op Inc Chg LTM | -3.0% |
| Op Inc Chg 3Y Avg | -46.9% |
| Op Mgn LTM | -434.3% |
| Op Mgn 3Y Avg | -1,272.8% |
| QoQ Delta Op Mgn LTM | -10.5% |
| CFO/Rev LTM | -346.9% |
| CFO/Rev 3Y Avg | -941.7% |
| FCF/Rev LTM | -349.2% |
| FCF/Rev 3Y Avg | -965.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 5.7 |
| P/S | 104.6 |
| P/Op Inc | -19.7 |
| P/EBIT | -19.9 |
| P/E | -19.5 |
| P/CFO | -26.6 |
| Total Yield | -5.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -8.1% |
| D/E | 0.0 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 0.3% |
| 3M Rtn | 27.5% |
| 6M Rtn | 72.8% |
| 12M Rtn | 218.2% |
| 3Y Rtn | 181.0% |
| 1M Excs Rtn | -8.4% |
| 3M Excs Rtn | 21.1% |
| 6M Excs Rtn | 57.0% |
| 12M Excs Rtn | 177.8% |
| 3Y Excs Rtn | 112.8% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Using innovative experimental and computational approaches on protein motion for making medicines | 10 | ||||
| Single Segment | 26 | ||||
| License and other revenue | 1 | 3 | |||
| Total | 10 | 26 | 1 | 3 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Using innovative experimental and computational approaches on protein motion for making medicines | -338 | ||||
| Total | -338 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Single Segment | 800 | ||||
| Total | 800 |
Price Behavior
| Market Price | $12.85 | |
| Market Cap ($ Bil) | 2.2 | |
| First Trading Date | 07/16/2020 | |
| Distance from 52W High | -23.5% | |
| 50 Days | 200 Days | |
| DMA Price | $12.31 | $7.90 |
| DMA Trend | up | up |
| Distance from DMA | 4.4% | 62.6% |
| 3M | 1YR | |
| Volatility | 72.1% | 70.7% |
| Downside Capture | 0.62 | 0.70 |
| Upside Capture | 290.64 | 274.07 |
| Correlation (SPY) | 24.8% | 31.3% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.22 | 1.53 | 1.50 | 1.38 | 1.71 | 1.82 |
| Up Beta | -0.03 | 0.58 | 1.26 | 3.02 | 1.97 | 1.75 |
| Down Beta | -3.34 | -0.34 | 0.75 | -0.60 | 0.66 | 1.76 |
| Up Capture | 513% | 382% | 397% | 293% | 625% | 723% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 13 | 23 | 35 | 64 | 133 | 356 |
| Down Capture | 671% | 135% | 32% | 61% | 111% | 112% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 9 | 20 | 29 | 60 | 113 | 386 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RLAY | |
|---|---|---|---|---|
| RLAY | 336.9% | 70.6% | 2.39 | - |
| Sector ETF (XLV) | 8.6% | 15.4% | 0.34 | 33.0% |
| Equity (SPY) | 28.1% | 12.5% | 1.78 | 31.4% |
| Gold (GLD) | 42.9% | 26.9% | 1.30 | 8.3% |
| Commodities (DBC) | 48.6% | 18.0% | 2.14 | -7.5% |
| Real Estate (VNQ) | 13.6% | 13.5% | 0.70 | 23.2% |
| Bitcoin (BTCUSD) | -22.4% | 41.7% | -0.50 | 18.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RLAY | |
|---|---|---|---|---|
| RLAY | -15.8% | 78.0% | 0.12 | - |
| Sector ETF (XLV) | 4.8% | 14.6% | 0.15 | 33.4% |
| Equity (SPY) | 12.9% | 17.1% | 0.59 | 38.8% |
| Gold (GLD) | 21.2% | 17.9% | 0.96 | 7.0% |
| Commodities (DBC) | 13.5% | 19.1% | 0.58 | 1.4% |
| Real Estate (VNQ) | 3.6% | 18.8% | 0.09 | 34.4% |
| Bitcoin (BTCUSD) | 8.5% | 56.0% | 0.36 | 19.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RLAY | |
|---|---|---|---|---|
| RLAY | -9.4% | 78.0% | 0.12 | - |
| Sector ETF (XLV) | 9.2% | 16.5% | 0.45 | 31.5% |
| Equity (SPY) | 15.0% | 17.9% | 0.72 | 36.6% |
| Gold (GLD) | 13.4% | 15.9% | 0.70 | 7.5% |
| Commodities (DBC) | 9.5% | 17.7% | 0.45 | 2.7% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.24 | 31.3% |
| Bitcoin (BTCUSD) | 68.1% | 66.9% | 1.07 | 17.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/26/2026 | 12.0% | 5.2% | 4.8% |
| 11/6/2025 | -7.4% | -1.2% | 16.1% |
| 8/7/2025 | -7.7% | -2.9% | 16.3% |
| 2/26/2025 | -13.3% | -9.6% | -20.3% |
| 11/6/2024 | -1.8% | -7.0% | -26.2% |
| 8/6/2024 | -7.9% | -8.8% | -9.7% |
| 5/2/2024 | -0.6% | -10.9% | -4.1% |
| 2/22/2024 | -5.4% | -5.2% | -26.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 8 | 9 |
| # Negative | 13 | 13 | 12 |
| Median Positive | 2.3% | 2.5% | 12.4% |
| Median Negative | -3.7% | -7.0% | -12.2% |
| Max Positive | 12.0% | 10.1% | 32.3% |
| Max Negative | -13.3% | -32.5% | -34.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/05/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/22/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Catinazzo, Thomas | Chief Financial Officer | Direct | Sell | 4092026 | 15.00 | 1,800 | 27,000 | 3,208,005 | Form |
| 2 | Catinazzo, Thomas | Chief Financial Officer | Direct | Sell | 4092026 | 13.01 | 17,717 | 230,498 | 2,782,410 | Form |
| 3 | Catinazzo, Thomas | Chief Financial Officer | Direct | Sell | 3112026 | 10.06 | 17,717 | 178,233 | 2,329,735 | Form |
| 4 | Bergstrom, Donald A | President, R&D | Direct | Sell | 1292026 | 8.45 | 2,686 | 22,697 | 3,549,397 | Form |
| 5 | Rahmer, Peter | See remarks | Direct | Sell | 1292026 | 8.45 | 1,354 | 11,441 | 2,337,354 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.